UnitedHealth Group kicks off earnings season for the health care sector Tuesday morning, and analysts are expecting double-digit sales and profit growth from the nation's largest health insurance and health care services firm. » Read More
By: Thomas Franck
Canopy Growth has been granted a license by New York State to process and produce hemp. » Read More
AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices. » Read More
By: Annie Pei
Biotech's having a huge run, but one technician is warning about the sector. » Read More
Privateer Holdings says it "strongly believes in Tilray's long-term global growth strategy and pioneering role" in legal cannabis.
While the numbers are milder than last season, the CDC's "influenza like illness level" last week was elevated at 4.1 percent, almost twice national baseline.
Two new deals to start the year and positive trial presentations at the J.P. Morgan Health Care conference have breathed new life into some of last year's biggest stock losers.
The bills, led by Sanders and Reps. Elijah Cummings and Ro Khanna, would permit Health and Human Services Secretary Alex Azar to negotiate lower prices for drugs under Medicare Part D, the federal program for prescription drug benefits.
Star investor Jeff Vinik, who just announced the revival of his hedge fund, doesn't see any money in cannabis stocks.
Researchers have developed a smartphone app that can detect an opioid overdose. Called Second Chance, the app accurately detects overdose-related symptoms by monitoring breathing patterns, then sends an alert so Narcan can be administered in time.
Canopy Growth shares surged 13 percent after Piper Jaffray initiates coverage of the cannabis industry, joining a growing list of brokerages watching the space.
Jim Cramer explains why renewed strength in the retail and housing stocks could make the Fed rethink the rate hike pause.
FDA Commissioner Scott Gottlieb's keynote address Tuesday was delivered via video conference from Washington, D.C., to thousands of bankers and health executives, and his audio cut out just as he was making a key point on teen nicotine use.
The National Cannabis Industry Association counters by saying: "So far, there is nothing to suggest that cannabis consumption causes mental illness."
Wall Street's top cannabis analyst believes U.S. marijuana sales will jump to $80 billion and expects Canopy and Tilray to outperform.
M&A activity in the fast growing health-care sector is expected to rebound in 2019, according to international law firm Baker McKenzie — but heavier regulation and political uncertainty could cloud the future.
Jim Cramer explains why it might be worth picking up shares of Micron now despite a possible negative quarter on the horizon.
Jim Cramer sits down with Amgen Chairman and CEO Bob Bradway to hear about the company's recent price cut for one of its key drugs.
Jim Cramer and Novartis CEO Vas Narasimhan discuss how the drugmaker is refocusing its business to leverage new-age treatments and potential cures.
Jim Cramer says leading drugmakers are innovating more than ever before and many of their stocks are worth owning.